Arvid Söderhäll, Empros Pharma CEO
Swedish biotech unveils topline data on weight loss drug designed for maintenance after GLP-1s
Empros Pharma’s oral weight loss drug only delivered an average 8% body weight reduction in its Phase IIb test. So it can’t battle with big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
